Roche buys U.S. diagnostics company IQuum in $450 million deal
ZURICH, April 7
ZURICH, April 7 (Reuters) - Swiss drugmaker Roche has agreed to buy privately-held U.S. diagnostics company IQuum in a deal worth up to $450 million to strengthen its molecular diagnostics business.
The Basel-based firm said it will pay IQuum shareholders $275 million upfront and up to $175 million in contingent product-related milestones.
"With IQuum, we further strengthen our molecular diagnostics offerings with cutting-edge technology and products that serve the point of care segment," said Roland Diggelmann, head of Roche's diagnostics division, in a statement on Monday. (Reporting by Caroline Copley; Editing by Christopher Cushing)
- Seven NATO allies to create new rapid reaction force-report
- Ukraine seeks to join NATO; defiant Putin compares Kiev to Nazis |
- U.S. authorities investigate suspected threat against Obama: reports
- Putin says Russia must strengthen its economic, military position in Arctic
- California passes 'yes-means-yes' campus sexual assault bill